leisure time -WSS

leisure time

author：Wikipedia 2025-10-03 00:22:19 - browse：24

Diversity in clinical trials concept — Adobe

The persistent lack of diversity among participants in clinical trials is a critical issue that is harming both populations that have long been left out of pivotal medical studies and the entire biomedical research enterprise, according to the authors of a report released Tuesday by the National Academies of Sciences, Engineering and Medicine.

Describing the need to move away from trials that focus largely on white men as “urgent,” the report’s authors called for a paradigm shift that gives less power to institutions that fund and conduct clinical research and more to communities under study. The sternly worded report said funding to include and recruit more diverse participants should be a priority that is enforced and said such investments could eventually lead to massive cost savings as the nation’s health disparities are reduced.

“An equitable clinical research enterprise would include trials and studies that match the demographics of the disease burden under study,” the report said. “However, we remain far from achieving this goal.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Meta's Zuckerberg and Chan on track to put $50 billion into science

WSS

Why Sanofi got shellacked over its spinoff

Scientists uncover potential path to treating deadly childhood tumor

Harvard scientists, with Google, unveil the most detailed brain map ever

Senate panel to vote on hospitals, PBMs, prisoner care

CDC recommends rationing of RSV shot due to shortages

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

focus

leisure time

Wikipedia

Heart attack and stroke risk calculators need revising

Meta's Zuckerberg and Chan on track to put $50 billion into science

New air purifier tech could be key to improving indoor air quality

Scientists uncover potential path to treating deadly childhood tumor

Psychedelics group wrestles with new pharma identity

The FDA weighs the risks of candy

Moonlake's readout produced a cash windfall. Risks remain

Scientists uncover potential path to treating deadly childhood tumor

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden's order seeks to regulate AI risk without stifling innovation

explore

Why Sanofi got shellacked over its spinoff

Study: Black kids more likely to die after surgery than white kids

U.K. decision on ALS drug has neurologists, advocates up in arms

Covid silver lining: Unprecedented look at human immune system

Four alarming medical procedures we’re glad history forgot

Paying for Covid pills will soon shift to insurers

leisure time

knowledge

hotspot

knowledge